Join us this episode for a conversation with Norbert Weidner, MD, Professor and Chair of the Spinal Cord Injury Center at Heidelberg University Hospital. In this conversation we discuss results of a clinical trial called the Neuroimmunophilin Nogo-A Antibody in Spinal Cord Injury (NISCI) trial. Findings from this trial were published in a paper titled "Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial" in the journal Lancet Neurology. In this paper Weidner and the NISCI team discuss the top-line findings from this large multi-center clinical trial where a drug (with antibodies against Nogo-A, a protein found in the walls of spinal cord neurons and their support cells) were given to people early after their accident. We invite you to listen in as Dr. Weidner gives an insider perspective on the NISCI trial, and trust you will enjoy our conversation on new pharmaology in the acute phase of SCI.